Literature DB >> 25581728

Clear cell myoepithelial carcinoma of salivary glands showing EWSR1 rearrangement: molecular analysis of 94 salivary gland carcinomas with prominent clear cell component.

Alena Skálová1, Ilan Weinreb, Martin Hyrcza, Roderick H W Simpson, Jan Laco, Abbas Agaimy, Marina Vazmitel, Hanna Majewska, Tomas Vanecek, Peter Talarčik, Spomenka Manajlovic, Simona N Losito, Petr Šteiner, Adela Klimkova, Michal Michal.   

Abstract

This study examines the presence of the EWSR1 rearrangement in a variety of clear cell salivary gland carcinomas with myoepithelial differentiation. A total of 94 salivary gland carcinomas with a prominent clear cell component included 51 cases of clear cell myoepithelial carcinomas de novo (CCMC), 21 cases of CCMCs ex pleomorphic adenoma (CCMCexPA), 11 cases of epithelial-myoepithelial carcinoma (EMC), 6 cases of EMC with solid clear cell overgrowth, and 5 cases of hyalinizing clear cell carcinoma of minor salivary glands. In addition, 10 cases of myoepithelial carcinomas devoid of clear cell change and 12 cases of benign myoepithelioma were included as well. All the tumors in this spectrum were reviewed, reclassified, and tested by fluorescence in situ hybridization (FISH) for the EWSR1 rearrangement using the Probe Vysis EWSR1 Break Apart FISH Probe Kit. The EWSR1 rearrangement was detected in 20 of 51 (39%) cases of CCMC, in 5 of 21 (24%) cases of CCMCexPA, in 1 of 11 (9%) cases of EMC, and in 4 of 5 (80%) cases of hyalinizing clear cell carcinoma. The 25 EWSR1-rearranged CCMCs and CCMCexPAs shared similar histomorphology. They were arranged in nodules composed of compact nests of large polyhedral cells with abundant clear cytoplasm. Necrosis, areas of squamous metaplasia, and hyalinization were frequent features. Immunohistochemically, the tumors expressed p63 (96%), cytokeratin CK14 (96%), and S100 protein (88%). MIB1 index varied from 10% to 100%, with most cases in the 20% to 40% range. Clinical follow-up information was available in 21 cases (84%) and ranged from 3 months to 15 years (mean 5.2 y); 4 patients were lost to follow-up. Ten patients are alive with no evidence of recurrent or metastatic disease in the follow-up period from 3 months to 15 years (mean 5 y), 3 patients are alive with recurrent and metastatic disease, and 8 died of disseminated cancer 9 months to 16 years after diagnosis (mean 6 y). Lymph node metastasis appeared in 5 patients within 5 months to 4 years after diagnosis (mean 22 mo), distant metastases were noted in 7 patients with invasion of orbit (2 cases), and in 1 case each metastasis to the neck soft tissues, liver, lungs, mediastinum, and thoracic vertebra was noted. We describe for the first time EWSR1 gene rearrangement in a subset of myoepithelial carcinomas arising in minor and major salivary glands. The EWSR1-rearranged CCMC represents a distinctive aggressive variant composed predominantly of clear cells with frequent necrosis. Most EWSR1-rearranged CCMCs of salivary glands are characterized by poor clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25581728     DOI: 10.1097/PAS.0000000000000364

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  33 in total

Review 1.  Applications of molecular testing in surgical pathology of the head and neck.

Authors:  Jennifer L Hunt
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

2.  A clear cell variant of mucoepidermoid carcinoma harboring CRTC1-MAML2 fusion gene found in buccal mucosa: report of a case showing a large clear cell component and lacking typical epidermoid cells and intermediate cells.

Authors:  Shogo Tajima; Ichiro Namiki; Kenji Koda
Journal:  Med Mol Morphol       Date:  2015-08-22       Impact factor: 2.309

Review 3.  [Updates on tumours of the salivary glands : 2017 WHO classification].

Authors:  S Ihrler; O Guntinas-Lichius; C Haas; M Mollenhauer
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

4.  Clinicopathological characteristics and cell cycle proteins as potential prognostic factors in myoepithelial carcinoma of salivary glands.

Authors:  F Passador-Santos; M Grönroos; J Irish; R Gilbert; P Gullane; B Perez-Ordonez; A Mäkitie; I Leivo
Journal:  Virchows Arch       Date:  2015-12-28       Impact factor: 4.064

5.  Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.

Authors:  Vivek Subbiah; Oliver Holmes; Kyle Gowen; Daniel Spritz; Behrang Amini; Wei-Lien Wang; Alexa B Schrock; Funda Meric-Bernstam; Ralph Zinner; Sarina Piha-Paul; Maria Zarzour; Julia A Elvin; Rachel L Erlich; David L Stockman; Jo-Anne Vergilio; James H Suh; Philip J Stephens; Vincent Miller; Jeffrey S Ross; Siraj M Ali
Journal:  Oncology       Date:  2016-10-21       Impact factor: 2.935

6.  Myoepithelial Carcinoma of the Nasopharynx: Report of a Rare Case and a Review of the Literature.

Authors:  Gwyneth Soon; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2015-06-27

7.  Adamantinoma-like Ewing Sarcoma of the Salivary Glands: A Newly Recognized Mimicker of Basaloid Salivary Carcinomas.

Authors:  Lisa M Rooper; Vickie Y Jo; Cristina R Antonescu; Vania Nose; William H Westra; Raja R Seethala; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2019-02       Impact factor: 6.394

Review 8.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12

9.  Thoracic Myoepithelial Tumors: A Pathologic and Molecular Study of 8 Cases With Review of the Literature.

Authors:  Charles Leduc; Lei Zhang; Buge Öz; Jean Luo; Junya Fukuoka; Cristina R Antonescu; William D Travis
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

Review 10.  [Diagnostic and predictive molecular pathology of head and neck neoplasms].

Authors:  A Agaimy; W Weichert; F Haller; A Hartmann
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.